Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has undergone a significant shift over the last year, moving from what he described a ...

CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus on expanding its pipeline while integrating the recently acquired Melinta ...

Cormedix Inc.’s latest earnings call struck a cautiously balanced tone, pairing record product sales, solid profitability, and strong liquidity with clear warning signs around future reimbursement and ...

Cormedix ( (CRMD)) has shared an announcement. On March 6, 2026, CorMedix, Inc. released an updated investor presentation outlining its institutional-focused pharmaceutical portfolio and reaffirmed ...

Total revenue -- $128.6 million in the fiscal fourth quarter ended Dec. 31, 2025, with primary growth from DEFENCATH and the first full-quarter contribution from the Melinta portfolio. Fiscal 2026 ...

The company is affirming 2026 DefenCath guidance of $150 million to $170 million, 2027 DefenCath guidance of $100 million to $125 million, and full year 2026 financial guidance of revenue of $300 ...

CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in late 2023 as the ...

The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...

The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...

DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...